Rationale: Mechanisms underlying vasomotor abnormalities and increased peripheral resistance exacerbating heart failure (HF) are poorly understood.
H eart failure (HF) is a progressive condition that affects more than 2% of the population and accounts for Ϸ$28 billion in health care costs in the United States. 1 The prevalence of HF is increasing worldwide, and given its adverse impacts on the quality and longevity of life, 1 the burdens imposed by HF are enormous. Irrespective of etiology, HF presents as a clinical syndrome of reduced cardiac output and or elevated cardiac filling pressures. [2] [3] [4] In the former, cardiac-renal-hormonal axes and sympathetic neural reflexes are activated in an attempt to maintain sufficient mean arterial pressure (MAP) for vital organ perfusion. 4 This is achieved through increased salt and water retention 4 (ultimately worsening the deleterious volume overload of HF), and through an increase in peripheral resistance (PR). 5 Although increased PR may support MAP in certain circumstances, chronic elevations in PR contribute to a pressure afterload that further limits cardiac output in HF, 3 and drives adverse cardiac remodeling. 3 Such "vicious cycles" are believed to play a key role in the progressive nature of HF, and many advances in its management have been aimed at mitigating this pathophysiology. In general, increased PR in HF is thought to be conveyed by neurohumoral activation, including the sympathetic nervous system, 6 the renin-angiotensin system (RAS), 4 and local mechanisms such as the myogenic response. 7 Our present purpose was to investigate the molecular mechanisms that underlie the latter, ie, myogenic elevations of PR in HF, to identify potentially novel therapeutic targets.
Indeed, growing evidence suggests that long-term elevations in PR depend more on "local" vascular mechanisms than systemic factors such as the sympathetic activation of orthostasis. 5 Moreover, reasons why chronic maintenance of high PR in HF by systemic sympathetic (ie, ␣ 1 -adrenergic) enhancement of peripheral vasoconstriction 2,8 is disadvantageous include: (1) increased sympathetic output compromises a failing myocardium (via tachycardia, arrhythmia, cytotoxicity 9 ); and (2) catecholamine potency diminishes because of adrenergic receptor desensitization. 10 -12 We thus posited that distinct local mechanisms would participate in chronic elevations in PR observed in HF. Supporting this premise, the maintenance of peripheral vascular tone largely depends on "myogenic" mechanisms intrinsic to vascular smooth muscle cells (VSMCs). 13 On a local level, myogenic mechanisms serve to adapt vascular tone to changes in transmural pressure. Systemically, myogenic vasoconstriction can amplify vasopressor responses by positive feedback on systemic blood pressure. This has been elegantly demonstrated by Metting et al, who showed that 74% of the phenylephrine (PE)-mediated increase in MAP relied on a myogenic mechanism. 14 Accordingly, we hypothesized that an increase in myogenic tone would underlie the long-term elevation of PR observed in HF. Although increased myogenic responses have been found in rats with HF, 7 a mechanistic explanation for this finding remained elusive. Based on our understanding of myogenic tone, [15] [16] [17] [18] [19] [20] [21] we sought to more fully explore the molecular pathways temporally activated in the resistance mesenteric arteries of mice with HF.
Our results reveal a heretofore unrecognized importance of S1P signaling in the development of increased PR in a mouse post-MI model of HF. In this model, we describe the rapid emergence of enhanced myogenic response, with its near complete dependence on the vascular signaling molecule S1P, the S1P 2 receptor (S1P 2 R) found on mesenteric arteries, and an unexpectedly Rho-independent inactivation of myosin light chain phosphatase (MLCP). Our finding of enhanced p38 MAPK and extracellular signal-regulated kinase (ERK)1/2 activation and the susceptibility of increased myogenic response of HF animals to a p38 MAPK inhibitor suggest novel therapeutic targets.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Reagents
Drugs, chemicals and antibodies were purchased from Sigma-Aldrich unless otherwise indicated, including L-phenylephrine (PE), acetylcholine chloride (ACh), sodium-nitroprusside (SNP), sphingosine-1-phosphate (S1P), D-erythro (Biomol International), the S1P 2 R antagonist JTE-013 (Trocris Bioscience), and the p38 MAPK inhibitor SB203580 (Cayman Chemical). Glutathione Stransferase-Rhotekin was prepared as described. 22 Additional reagents are described in the Online Data Supplement.
Animals
Experiments were conducted in accordance with protocols approved by our institutional Animal Care Committee. Wild-type male C57BL/6 mice (Charles River) and knockout strains were housed under 12 hour:12 hour light-dark cycles with normal chow and water ad libitum. Mice at 10 weeks of age underwent surgery to induce a myocardial infarction (MI) or a sham procedure, as described. 23 Mice were euthanized at prespecified time points 1 to 12 weeks postoperative.
Hemodynamics and Echocardiography
Aortic and left ventricular pressure measurements were made as described. 24 Transthoracic echocardiography was conducted under identical anesthesia using a 30 MHz mechanical sector transducer (Vevo 770, Visual Sonics). Measurements and calculations used are described in the Online Data Supplement.
Perfusion Myography
Mice were euthanized and either mesenteric, posterior cerebral or cremaster muscle arteries were rapidly dissected and prepared for perfusion myography as detailed in the Online Data Supplement. Viability of the vessel preparations was assessed using 3 mol/L PE; endothelial viability was subsequently assessed with 3 mol/L ACh. Concentration-dependent vasoconstriction relationships for PE (1 nmol/L-30 mol/L), ET-1 (0.01 nmol/L-10 nmol/L) and S1P (1 nmol/L-10 mol/L) were determined. Concentration-dependent vasodilation to ACh (1 nmol/L-30 mol/L) and SNP (1 nmol/L-30 mol/L) were determined in arteries preconstricted with 3 mol/L PE. In some experiments, vessels were treated with S1P2R antagonist JTE-013 (1 m; 30 minutes) following dose-response assessments and then retested. At the completion of each experiment, a Ca 2ϩ -free buffer was used to record passive diameter (dia passive ). Vessel tone was calculated as: (dia passive Ϫdia response )/dia passive , where dia response is the diameter at a given drug concentration. To assess the myogenic response, transmural pressure was increased in 20 mm Hg steps from 20 to 120 mm Hg. Vessel diameter (active) was measured at each pressure step once a steady state was reached (5 to 10 minutes). In some experiments, vessels were treated with JTE-013 (1 mol/L; 30 minutes) or SB203580 (5 mol/L; 30 minutes) following the myogenic response assessment and retested. At completion, passive diameter (dia passive ) was recorded for each pressure step. Myogenic tone at each step was calculated as: (dia passive Ϫdia active )/dia passive . Myogenic index, a measure of the strength of the myogenic response at each pressure step, was calculated as previously described. 25 
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Histology, Western Blot, VSMC Isolation, and RT-PCR
These details are provided in the Online Data Supplement.
Statistical Analysis
All data are expressed as meansϮSE; n values represent the number of mice or arteries (although no more than 1 artery segment per mouse was used for the same protocol). All data were analyzed with a Student's unpaired t test, with the exception of myogenic responses, which were analyzed with repeated measures ANOVA, followed by t-tests with Bonferonni correction. PCR and Western blot data were analyzed as described above. For a comparison between control and treatment groups the resulting relative expression ratios were directly compared using a Student's unpaired t test. Differences were considered significant at PϽ0.05.
Results
HF Develops in Mice After MI
The left anterior descending (LAD) ligation model generated a reproducible infarct size (33.6Ϯ1.1%, nϭ40) with compelling evidence of HF never observed in sham-operated controls (Table) . Compared to sham, post-MI animals showed evidence of fluid retention and organ congestion as manifest by increased body, heart, lung, and liver weights and an increase in the heart:body weight ratio at 1, 2, 4, 6, and 12 weeks after MI. At 1 and 6 weeks after MI, echocardiography revealed left ventricular dilatation (1 week: 5.1Ϯ0.6 mm, nϭ4, versus 3.8Ϯ0.3 mm, nϭ6; 6 weeks: 6.5Ϯ0.1 versus 4.5Ϯ0.1 mm, nϭ5 for both; PϽ0.001 for both), with reduced fractional shortening (1 week: 12Ϯ1 versus 26Ϯ2; 6 weeks: 8Ϯ1 versus 28Ϯ2; %, PϽ0.0001 for both) and ejection fraction (Table) . Other signs of cardiac contractile dysfunc-tion included diminished stroke volume and reduced cardiac output ( Figure 1A ; Online Figure I, A) developed without differences in heart rate (HR) between HF and sham groups (Table) . A significant increase in calculated PR was also found in the HF group ( Figure 1B 
Resistance Artery Structure Is Not Altered in Mice With HF
To examine whether structural changes in resistance arteries accompany observed increases in PR, media mass and collagen content were assessed in histological sections of second order mesenteric arteries from mice with HF as compared to sham controls. At 6 weeks after surgery, neither parameter was different between the two groups, with maximal passive mesenteric artery diameters further suggesting an absence of structural remodeling (Online Figure II ).
Resistance Artery Functions Are Specifically Altered in Mice With HF
Mesenteric arteries from HF and sham were subjected to a series of vasomotor studies to determine both the nature and extent of functional differences. Concentration-dependent vasoconstriction to the ␣ 1 -agonist PE tested at 1 week after MI showed reduced responsiveness in mesenteric arteries from animals with HF versus sham controls (Figure 2A ). In contrast, concentration-dependent vasoconstriction to PE at all later time points did not differ between HF and sham mice ( Figure 2B ; data not shown for 2, 4, 12 weeks). Indeed, a PE dose (3 mol/L) induced near identical levels of vessel preconstriction at 6 weeks postoperative (HF: 71Ϯ2.5; sham: 70.6Ϯ2.6; % passive diameter at 60 mm Hg; PϭNS), following which applications of ACh and SNP were used to assess endothelium-dependent and endothelium-independent vasodilatory responses respectively. Neither ACh nor SNP doseresponse relationships differed between HF versus sham groups (Online Figure III In contrast to these results, vasoconstrictor responses to increasing concentrations of ET-1 (0.01 to 10 nmol/L) were greater in mesenteric arteries from animals with HF versus sham (Online Figure IV, A) . To examine if this was a function of enhanced Ca 2ϩ sensitivity of the contractile apparatus, mesenteric arteries were exposed to increasing concentrations of extracellular Ca 2ϩ (0.25 to 3.0 mmol/L) in perfusion buffers containing a depolarizing level of K ϩ (125 mmol/L). Under these conditions, no difference was found in Ca 2ϩ sensitivity (data not shown). Together, these studies suggested that the increase in ET-1 sensitivity that accompanies the development of HF in mice was a ligand/ receptor-specific effect of enhanced pharmacomechanical (but not electromechanical) coupling.
Increased Myogenic Responses in HF Becomes
More S1P 2 R-Dependent Over Time
We next assessed whether pressure-induced (ie, myogenic) vasoconstriction was increased in mice with HF. Myogenic responses to perfusion pressures 20 to 120 mm Hg were markedly increased in mesenteric arteries from HF versus sham-operated mice ( Figure 3A through 3D), including significant increases in the "resting tone" (defined as the myogenic tone at perfusion pressure 60 mm Hg; PϽ0.05 for all time-points; Figure 3 ) and the "myogenic index" (Online Figure V) . Having recently shown that the phospholipid mediator S1P is an integral component of the pathway that regulates the myogenic response in hamster, 17 we sought to explore a similar role for S1P in mice with HF. In this regard, the S1P 2 R-selective inhibitor JTE-013 reduced myogenic response in arteries from sham mice by only modest levels (28.0Ϯ4.5% at 120 mm Hg) at all time points tested. Although mesenteric arteries from HF mice showed a similarly limited contribution of S1P to the myogenic response at 1 week after MI (ie, JTE-013-induced inhibition of myogenic response was 30.8% at 120 mm Hg; Figure 3A ), this proportion substantively increased at later time points (2, 4, and 6 weeks postoperative: 88.5%, 88.1%, and 84.1%; Figure 3B through 3D). This result indicated that the enhanced myogenic response of mice with HF becomes more S1P 2 Rdependent more than time. Importantly, JTE-013 had no effect on ET-1-induced vasoconstriction (Online Figure IV, B) .
To ascertain whether the increased myogenic responses of mesenteric arteries observed in HF was a generalized effect, perfusion myography was also conducted on posterior cerebral arteries (data not shown) and cremaster skeletal muscle arterioles ( Figure 4 ). These studies confirmed increased myogenic responses in each vascular bed examined in HF, and thus a generalized systemic effect of HF consistent with hemodynamic evidence of increased PR ( Figure 1B ; Online Figure I 
Myogenic Responses in Mesenteric Arteries From Mice Without HF Only Partially Depend on S1P/S1P 2 R
Having previously reported a key role for S1P and S1P 2 R in regulating the myogenic response in hamster, 17 we had expected the S1P 2 R antagonist JTE-013 to have significant effects on the myogenic response of mesenteric arteries from both HF and sham mice. We were thus surprised to observe the limited effect of S1P 2 R blockade on myogenic responses in mesenteric arteries from sham mice (Figure 3) , and sought additional evidence to support this finding. We examined myogenic responses in mesenteric arteries isolated from mice with genetic deletion of sphingosine kinase-1 (Sphk1 Ϫ/Ϫ ), 24 the predominant source of pressure-induced S1P synthesis in hamster. 17 The myogenic response elicited by a pressure step from 45 to 110 mm Hg in mesenteric arteries from Sphk1 Ϫ/Ϫ and wild-type littermates were virtually identical (109Ϯ8%, nϭ5 versus 102Ϯ9%, nϭ5, PϭNS), suggesting that genetic absence of Sphk1 Ϫ/Ϫ can be completely compensated for, and supporting our observation that S1P/S1P 2 R may only partially mediate myogenic responses in mesenteric arteries isolated from animals without HF (ie, in sham-or unoperated mice, Figure 3 ). Consistent with previous data from hamster, 17 myogenic responses of cremaster and cerebral arteries were fully mediated by S1P (ie, abrogated by JTE-013, Figure 4A and data not shown) and enhanced in arteries from HF mice.
Effects of S1P on Mesenteric Arteries From Animals With HF
To further explore the role of S1P/S1P 2 R in myogenic responses in HF, the S1P dose-response relationship was examined in HF and sham mice. These studies revealed greater vasoconstriction at every S1P concentration tested (1 nmol/L-10 mol/L) in the HF group ( Figure 5 ). With the exception of the highest S1P concentration tested (10 mol/ L), the enhanced vasoconstriction to S1P observed in mice with HF was entirely attributable to S1P 2 R activation, as gauged by the effects of JTE-013 ( Figure 5B ). Consistent with this result, we were unable to detect mRNA encoding any S1P receptor other than S1P 2 R in either whole mesenteric arteries or VSMCs isolated from mesenteric arteries (Online Figure VI) . HF in Sphk1 ؊/؊ , Sphk1 ؊/؊ /Sphk2 ؉/؊ , and S1P 2 
R ؊/؊ Mice Was Not Associated With Enhanced Myogenic Response
To further investigate the importance of the S1P/S1P 2 R signaling pathway in the regulation of myogenic response in HF, genetic mutants of the S1P signaling pathway were also subjected to experimental MI. Unlike the wild-type, none of the mutants tested manifest enhanced myogenic response at 4 weeks after MI (Online Figure VII) . Having said this, Sphk1 Ϫ/Ϫ /Sphk2 ϩ/Ϫ mice were still able to increase PR at this time-point in HF as compared to sham-operated controls (Online Figure VIII) .
MLCP Is Inactivated in Mice With HF
To determine molecular mechanisms underlying our findings, we first measured levels of activated (ie, Ser19 phosphorylated) myosin light chain (MLC) in mesenteric arteries from animals 6 weeks after MI or sham surgery. As expected, Ser19 phosphorylation of MLC was 28.0Ϯ5.9% greater in mesenteric arteries from HF versus sham ( Figure 6A , Pϭ0.04), a result consistent with enhanced activity of MLCspecific kinase (MLCK) or diminished activity of MLCspecific phosphatase (MLCP) in HF.
As the balance between MLCK and MLCP activities determines the contractile status of VSMCs, 26 we next examined levels of active and inactive MYPT1, the regulatory subunit of MLCP. Relative amounts of inactive MLCP (ie, Thr850-phosphorylated MYPT1) were 2.33Ϯ0.15 fold greater in mesenteric arteries from HF than sham ( Figure  6B ). This result suggested that inactivation of MLCP plays a major role in the ligand/receptor-specific vasoconstrictor responses and increased myogenic response and PR documented in HF.
We next studied which of the several known upstream regulators of MYPT1 may be mediating the effects observed in HF. First, it is known that Rho-kinase phosphorylates MYPT1, inactivating MLCP and enhancing vasoconstrictor responses, including Ca 2ϩ sensitivity in VSMCs. 27 As Rho cycles between GDP (inactive) and GTP (active) forms, we directly measured levels of GTP-Rho in mesenteric arteries with an established pull-down assay using GST-Rhotekin. 27 To our surprise, we found that levels of GTP-Rho were markedly reduced in mesenteric arteries from mice with HF ( Figure 6C ). This result strongly suggested that the inactivating phosphorylation of MYPT1 seen in HF was not mediated by GTP-Rho/Rho-kinase.
Mesenteric Arteries of Mice With HF Manifest Increased Activation of p38 MAPK and ERK1/2
In VSMCs, a specific MLCP inhibitor known as CPI-17 has been described. 28 Both Rho-kinase and protein kinase C are known to Thr38-phosphorylate CPI-17, which dramatically increases its ability to inhibit MLCP. 28 Additional upstream negative regulators of MYPT1, including zipper interacting protein kinase (ZIPK) 29 and integrin-linked kinase (ILK) 30 were also examined in mesenteric arteries from HF and sham mice. Western blots revealed a nonsignificant increase in Thr38-phosphorylation of CPI-17 (CPI-17: 1.33Ϯ0.15 versus 1.00Ϯ0.11, nϭ8, PϭNS) and no significant differences in expression levels of ZIPK and ILK (data not shown). Having said this, we have not directly measured activity levels of the latter kinases.
To examine other upstream regulators of MLCP, we next assayed known protein kinase C-dependent mitogen-activated protein kinases (MAPKs) known to inhibit MYPT1 of gut smooth muscle via ZIPK and ILK, namely p38 MAPK and ERK1/2. [31] [32] [33] Western blots revealed that activating Thr202/Tyr204-phosphorylation of ERK1/2 was modestly increased in mesenteric arteries of mice with HF as compared to sham controls (Online Figure IX, A) . This change was dwarfed by the large increase in levels of phosphorylated (ie, active) p38 MAPK observed in mesenteric arteries from animals with HF versus sham (2.21Ϯ0.24 versus 1.00Ϯ0.31, nϭ4, Pϭ0.004) ( Figure 6D ).
To assess whether p38 MAPK and ERK1/2 in intact mesenteric arteries are subject to activation by S1P, Western blots were performed on protein extracts from mesenteric arteries of wild-type uninjured mice exposed to S1P (2 mol/L x 10 minutes). Although levels of phospho-ERK1/2 were increased (Online Figure IX, B) , no activation of p38 MAPK was observed following this acute treatment protocol (data not shown). However, in the chronic HF setting, a p38 MAPK inhibitor completely abolished the increased myogenic response of mesenteric arteries, having significantly less effect on the myogenic response of mesenteric arteries isolated from sham animals (Figure 7 ).
Discussion
Our ex vivo studies of isolated mesenteric arteries from mice with HF and increased PR have revealed (1) enhanced myogenic responses and (2) augmented vasoconstrictor re- sponses to specific ligands, without structural vascular remodeling or a generalized increase in Ca 2ϩ sensitivity of the contractile apparatus. 19 We also discovered (3) that although S1P and S1P 2 R signaling plays a minor role in regulating the myogenic response of mesenteric arteries from control animals, or from those animals in the early stages of HF (Ͻ2 weeks), S1P and S1P 2 R play a dominant role in the myogenic responses of normal mouse cremaster arterioles and in the pathophysiology of enhanced myogenic responses of all vascular beds examined as HF progresses over time. Indeed, in the later stages examined (2 to 12 weeks; see Figure 3 ), myogenic responses of mesenteric arteries became almost entirely dependent on S1P/S1P 2 R signaling. Importantly, increased myogenic tone was a generalized response of all systemic arteries examined, as it held true in both posterior cerebral (data not shown) and cremaster muscle resistance vessels (Figure 4 ). Our molecular studies of this model further defined (4) that its vascular phenotype may at least partly depend on enhanced activities of p38 MAPK and ERK1/2 and their ability to effect (5) inactivating phosphorylation of MYPT1, the regulatory subunit of MLCP. Although links between S1P and activation of both p38 MAPK and ERK1/2 have been established in smooth muscle, 34, 35 our finding of complete susceptibility of the enhanced myogenic response in chronic HF to a p38 MAPK inhibitor is of particular therapeutic interest. Taken together, this study brings forth a fundamental mechanism underlying the chronically elevated PR observed in HF and provides new testable targets.
In this study, we used an established model of MI-induced HF in mice. 36 LAD ligation resulted in Ϸ30% infarct of the left ventricle, resulting in all the hallmarks of HF (Table) , including calculated increases in PR consistent with previous reports. 7 Increased vascular tone and PR may stem from alterations in resistance artery structure and/or function. Indeed, indirect evidence of altered vascular structure has been reported in human subjects with HF. 37, 38 However, in the relatively short-term (12 weeks) model studied here, we failed to detect any significant structural changes in mesenteric arteries isolated from mice with HF. As such, we believe that vascular remodeling contributes minimally to the observed increases in vascular tone at these stages, and that the elevations in PR described are based primarily on functional perturbations.
To explore the latter, we performed extensive vasomotor analyses. Near identical PE and NEPI dose-response relationships for mesenteric and cremaster arteries respectively from mice with established HF and sham indicated that enhanced adrenergic sensitivity is not responsible for chronically elevated PR of HF. We also excluded reduced responsiveness of mesenteric arteries to endothelium-derived (ACh) or exogenous (SNP) sources of nitric oxide, a finding consistent with a report in rat, in which endothelium-derived mediators were found not to account for differences in myogenic responses in HF. 7 However, as "endothelial dysfunction" has been documented in conduit brachial arteries of patients with chronic HF, 39 the absence of impaired ACh-induced vasodilation in our model was unexpected, and may reflect pathophysiological differences between species, conduit versus resistance arteries, or the relatively short-term nature of our model. We have also not excluded the possibility of a HF-associated shift from NO to EDHF (endothelium-derived hyperpolarizing factor) as the dominant endothelium-derived vasodilator, 40 and further studies examining flow-mediated vasodilation are required to probe this issue further.
The regulation of myogenic response represents an additional distinct means of modulating vascular function. Myogenic mechanisms are capable of efficiently maintaining elevated levels of vascular tone over an extended period of time, because they: (1) do not require systemic neurohumoral activation; (2) can be controlled locally; and (3) can uncouple the Ca 2ϩ signal from vasoconstriction over time. 21 Accordingly, the majority of PE-mediated increases in MAP in conscious dogs 14 (and hamsters 41 ) has been shown to depend on a myogenic mechanism. 13, 14, 42 As hypothesized, mesenteric arteries from mice with post-MI HF displayed a dramatic increase in myogenic response as compared to controls. This may explain the increased PR observed in mice with HF in vivo, in the absence of any overt alteration in the Ca 2ϩ sensitivity of isolated mesenteric arteries. As a methodological note, the present experimental model maintained constant pressure when vasomotor responses were elicited (ie, there was no systemic pressure on which the myogenic tone would exert feedback). Thus, the observed enhancement in myogenic tone would not be observed in (or explain) any of the ligand dose-response experiments.
The regulation of myogenic tone involves both Ca 2ϩdependent (transmembrane Ca 2ϩ flux) and Ca 2ϩ -independent (RhoA signaling) mechanisms. 21 Mediators that orchestrate these two fundamental processes thus represent master controls that ultimately determine the extent of the myogenic response. We have previously shown that S1P signaling plays a central role in regulating the myogenic response of hamster skeletal muscle arteries, where it modulates both pressurestimulated elevations in intracellular Ca 2ϩ and Ca 2ϩ - independent mechanisms. The latter are attributed to extracellular S1P, which is synthesized and released by Sphk1 in response to pressure elevations and acts via the S1P 2 R to activate RhoA/Rho kinase 17 and Rac1 20 signaling cascades to ultimately inhibit MLCP. It is noteworthy, that of the three vascular S1P receptor subtypes (S1P 1 -, S1P 2 -and S1P 3 -), 43, 44 mouse mesenteric arteries as well as isolated VSMCs from mouse mesenteric arteries (where contamination by endothelial mRNA can be excluded) predominantly express S1P 2 R mRNA (Online Figure VI, B) .
However, in terms of regulating myogenic response of mouse mesenteric arteries, S1P/S1P 2 R signaling appears to be of limited significance in sham controls, where S1P 2 R blockade attenuated myogenic response by only Ϸ30%. This result was unexpected, as we had previously shown that S1P is a critical regulator of myogenic response in hamster. 17 In this prior study, hamster skeletal muscle arteries were transfected with a dominant-negative mutant of Sphk1 (Sphk1 G82D ) 45 and a distinct "1-step" perfusion pressure protocol to induce myogenic response was used. 17 Thus, to obviate methodological differences, we tested myogenic response via the 1-step protocol in mesenteric arteries isolated from Sphk1 Ϫ/Ϫ mice (see the Online Data Supplement). Our finding that myogenic responses were similar in Sphk1 Ϫ/Ϫ and wild-type vessels suggests that genetic absence of Sphk1 throughout development can be completely compensated for.
In stark contrast to vessels from sham controls, S1P/S1P 2 R signaling dominates the regulation of myogenic response in mesenteric arteries of mice with HF, as manifest by the complete abrogation of myogenic responses following S1P 2 R blockade with JTE013 in mice 2 or more weeks after LAD ligation ( Figure 3B through 3D) . Mesenteric artery vasoconstriction in response to exogenously applied S1P is also dramatically enhanced in HF (Figure 4) , a result consistent with the emerging importance of S1P in the regulation of myogenic responses. It is worth noting that the shift toward a dominant role for S1P signaling in the regulation of myogenic responses is not immediate. Despite clearly increased myogenic responses (and PR, see Online Figure I ) at 1 week after LAD ligation, the relative contribution of S1P/S1P 2 R signaling at this early stage is similar to that of controls ( Figure  3A) . Indeed, there is substantial evidence for sympathetic activation in the early stages of HF, 46 and our own observation of reduced responses to PE at lower (ie, physiological) doses at 1 week after MI may suggest "desensitization" over physiological concentrations even though the experimental EC 50 appeared unchanged (Figure 2A) . Further attesting to the critical importance of S1P/S1P 2 R in inducing and or maintaining elevated PR in HF, we failed to document any differences in myogenic response between sham and HF mice lacking Sphk1 (Sphk1 Ϫ/Ϫ ), Sphk1 and one allele of Sphk2 (Sphk1 Ϫ/Ϫ /Sphk2 ϩ/Ϫ ; the double knockout being embryonic lethal), and S1P 2 R (S1P2R Ϫ/Ϫ ) (Online Figure VII) . Indeed, future studies aimed at determining other systemic (ie, "nonmyogenic" or "nonmesenteric") mechanisms by which Sphk1 Ϫ/Ϫ /Sphk2 ϩ/Ϫ mice increase PR during HF may be of particular interest (Online Figure VIII) .
Although S1P is capable of regulating Ca 2ϩ -dependent and -independent mechanisms, both of which govern the myogenic response, 21 our data from this HF model suggest that Ca 2ϩ -independent mechanisms predominate. By definition, Ca 2ϩ sensitivity of the contractile apparatus reflects the ratio of activities of MLCK to MLCP. 26 The balance between MLCK and MLCP ultimately dictates the phosphorylation status of MLC 20 , which controls contraction. MLCK activity is dependent on intracellular Ca 2ϩ levels ([Ca 2ϩ ] i ), 26 whereas the modulation of MLCP activity allows the phosphorylation status of MLC 20 to be altered independent of [Ca 2ϩ ] i . The inherent advantage of uncoupling contraction from [Ca 2ϩ ] i is that chronic vascular tone can be maintained at resting Ca 2ϩ levels; conserving energy-requiring Ca 2ϩ cycling for other critical processes.
Several lines of experimental evidence support the notion that Ca 2ϩ -independent mechanisms are key to maintaining PR in mesenteric arteries from mice with HF: (1) greater abundance of Ser19-phosphorylated MLC 20 ; (2) greater abundance of Thr850-phosphorylated MYPT1, the inactivating subunit of MLCP; (3) dramatically decreased Rho-kinase activity, which is normally a key mediator of enhanced Ca 2ϩ sensitivity; and (4) an unaltered [Ca 2ϩ ] ext -vessel diameter relationship, together implicating a heretofore unrecognized "Rho-independent" mechanism for the inhibition of MLCP activity in resistance arteries in HF. Finally (5), the findings of increased p38 MAPK and ERK1/2 activation in mesenteric arteries of HF animals, and (6) the ability of a p38 MAPK inhibitor to abolish the increased myogenic response of HF but not sham arteries (Figure 7) shed new light on the pathways involved in maintaining elevated PR. Although the p38 MAPK inhibitor had little (if any) effect on the myogenic response of mesenteric arteries from sham animals, the same inhibitor has been shown to blunt myogenic responses of rat skeletal muscle arterioles. 47 Together, these data suggest that p38 MAPK exerts species/vessel-and disease-specific influence on the myogenic response.
Finally, "upstream" signals that may have led to the adaptive shifts in vasomotor function observed in our model of HF are worthy of discussion. For example, Gschwend et al showed that blockade of AT 1 receptors with angiotensin receptor blockers reversed the increased myogenic constriction observed in HF in rat, 7 suggesting participation of RAS, which has also been linked directly (and indirectly via NADPH oxidase-derived ROS 48 ) to Sphk-dependent vasomotor effects in isolated vessel preparations from nondiseased animals 20, 49 and to p38 MAPK activation in VSMCs. 48 Further studies will be needed to dissect the precise contributions of RAS, other neurohormones, or even cytokines implicated in HF such as tumor necrosis factor-␣, 50 to Sphk activity, 51,52 S1P receptor expression, 52 and myogenic responses.
In summary, we have shown that the myogenic response is strongly augmented in mesenteric, posterior cerebral, and cremaster muscle arteries from mice with HF. As HF progresses, S1P/S1P 2 R signaling emerges as a dominant mechanism regulating this increased myogenic response, acting via inhibited MLCP activity and possibly via enhanced activation of p38 MAPK and ERK1/2, known activators of the inhibitory effects of ZIPK and ILK on the MYPT1 subunit of MLCP in smooth muscle. Because this is a potentially critical mechanism that serves to increase vascular tone on a chronic basis, it may represent a novel therapeutic target for the treatment of HF. Indeed, the functional effects of a p38 MAPK inhibitor on myogenic responses in HF, as but one example of a drug target in the pathway identified, strongly supports this notion.
